Bioventus Inc. (BVS) NASDAQ
8.06
+0.13(+1.64%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
8.06
+0.13(+1.64%)
Currency In USD
| Previous Close | 7.93 |
| Open | 7.93 |
| Day High | 8.14 |
| Day Low | 7.81 |
| 52-Week High | 11.25 |
| 52-Week Low | 5.81 |
| Volume | 694,741 |
| Average Volume | 526,426 |
| Market Cap | 546.05M |
| PE | 19.66 |
| EPS | 0.41 |
| Moving Average 50 Days | 9.69 |
| Moving Average 200 Days | 8.09 |
| Change | 0.13 |
Bioventus to Report Fourth Quarter of Fiscal Year 2025 Financial Results on March 5, 2026
GlobeNewswire Inc.
Feb 24, 2026 9:15 PM GMT
DURHAM, N.C., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal y
Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 12:30 PM GMT
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Con
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 9:15 PM GMT
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, Bioventus President and Chief Executive Officer, will present at the Piper Sandler